Microvascular Dysfunction in Hypertrophic Cardiomyopathy.
Francesco PellicciaFranco CecchiIacopo OlivottoPaolo G CamiciPublished in: Journal of clinical medicine (2022)
Myocardial ischemia is an established pathophysiological feature of hypertrophic cardiomyopathy (HCM) that impacts various clinical features, including heart failure (HF) and sudden cardiac death (SCD). The major determinant of myocardial ischemia in HCM is coronary microvascular dysfunction (CMD) in the absence of epicardial coronary artery abnormalities. Despite the impossibility to directly visualize microcirculation in vivo, a multimodality approach can allow a detailed assessment of microvascular dysfunction and ischemia. Accordingly, the non-invasive assessment of CMD using transthoracic Doppler echocardiography, positron emission tomography, and cardiac magnetic resonance should now be considered mandatory in any HCM patient. Noteworthy, a complete diagnostic work-up for myocardial ischemia plays a major role in the approach of the patients with HCM and their risk stratification. Chronic and recurrent episodes of ischemia can contribute to fibrosis, culminating in LV remodeling and HF. Ischemia can potentially constitute an arrhythmic substrate and might prove to have an added value in risk stratification for SCD. Accordingly, strategies for the early diagnosis of CMD should now be considered an important challenge for the scientific community.
Keyphrases
- hypertrophic cardiomyopathy
- left ventricular
- heart failure
- coronary artery
- cardiac resynchronization therapy
- positron emission tomography
- aortic stenosis
- magnetic resonance
- computed tomography
- oxidative stress
- healthcare
- acute heart failure
- mental health
- magnetic resonance imaging
- coronary artery disease
- machine learning
- pet imaging
- pulmonary arterial hypertension
- drug induced
- blood flow
- atrial fibrillation